From submission to surveillance: rethinking market entry as a lifecycle strategy

For many biopharma organizations, market authorization (MA) represents a defining milestone after years of research, development and regulatory preparation. But in today’s increasingly complex global environment, approval is not the endpoint of market entry. In reality, it is the transition point into a much longer and more operationally complicated phase of a product’s life cycle.

Regulatory responsibility extends across years or even decades of maintaining a product in-market across multiple regions, while continuously adapting to evolving safety expectations, regulatory requirements, manufacturing changes and geographic expansion. As sponsors scale globally and enter diverse markets, market entry must be reframed as a continuous life cycle, spanning dossier preparation through post-approval pharmacovigilance (PV) and regulatory maintenance.

PPD™ FSP Regulatory Affairs solutions and PPD™ FSP Pharmacovigilance solutions experts find that organizations that adopt this lifecycle mindset are better positioned to manage compliance, scale globally and sustain long-term product value. Achieving this requires integrated regulatory and PV strategies, supported by scalable operating models, technologies and expertise.

The expanding scope of market entry

Historically, MA has often served as the primary operational focus during commercialization planning. Biopharma organizations typically prioritize the complex work required to achieve submission and approval milestones within aggressive timelines. But the demands placed on sponsors today extend well beyond the approval phase.

Regulatory and PV obligations begin at submission and continue indefinitely. Keeping a product in-market requires ongoing lifecycle maintenance activities that span regulatory updates, renewals, manufacturing and labeling changes, safety reporting and market expansion into new geographies or patient populations. This means that successful commercialization depends not only on achieving approval, but on sustaining operational readiness long after launch. Approval, therefore, is not the “end of development,” but the start of operational accountability at scale.

The growing complexity of post-approval requirements

According to PPD FSP Regulatory Affairs solutions experts, once a product enters the market, the operational burden intensifies significantly. Sponsors must maintain ongoing safety monitoring programs, manage continuous individual case safety reports (ICRSs), conduct signal detection activities and execute risk management plans. At the same time, they must respond to evolving regulatory updates, manufacturing and process changes, and market expansions into new geographies and patient populations.

Compounding this challenge is the fact that global regulatory expectations remain highly fragmented. For example, in the European Union, organizations are required to have a Qualified Person for Pharmacovigilance (QPPV), Pharmacovigilance System Master File (PSMF) and Risk Management Plan (RMP) for lifecycle management. In the United States, sponsors must maintain robust safety reporting through the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) and potentially support Risk Evaluation and Mitigation Strategy (REMS) if required. In Japan and other APAC markets, localized PV expectations including early post-marketing phase vigilance (EPPV) introduce additional complexity.

Even with Common Technical Document (CTD) harmonization, post-approval requirements vary significantly across global regulatory bodies. As a result, lifecycle maintenance requires constant monitoring, updates and coordination across functions and regions along with the ability to adapt quickly as regulations and operational needs evolve.

Why lifecycle thinking matters more than ever

The need for lifecycle-focused development strategies is becoming more urgent as sponsors expand into new regions faster than ever before. At the same time, products often remain on the market for decades, far exceeding timelines associated with development and approval. Over that lifespan, organizations must manage an ongoing stream of operational changes, including manufacturing and label updates, safety reporting obligations, new indications, and geographic expansions. This complexity is further amplified by increasing regulatory scrutiny, evolving global requirements and growing volumes of safety data.

To manage this effectively, organizations need:

• Scalable PV systems and infrastructure
• Consistent global processes
• Integrated regulatory and PV operations
• Technology enablement through artificial intelligence (AI)-driven PV platforms and global workflow management (follow-the-sun operations)

Importantly, lifecycle thinking enables organizations to move from reactive compliance management to more proactive operational planning. Maintaining a reactive approach to these issues introduces inefficiencies and challenges, including risks of delayed submissions, inconsistent compliance across markets and even potential product withdrawal or market disruption due to noncompliance. Instead of responding to issues after they emerge, lifecycle-driven organizations are better positioned to:

• Anticipate regulatory changes
• Scale efficiently into new markets
• Sustain long-term product value
• Maintain consistent compliance standards

The FSP model as a life cycle enabler

As lifecycle management becomes more complex, many organizations are reevaluating how they structure regulatory and PV operations. Increasingly, sponsors are turning to FSP models to create more scalable, integrated approaches to lifecycle management. An FSP model transforms life cycle complexity into an operational advantage through centralized oversight, embedded expertise, scalable resourcing and integrated infrastructure.

PPD FSP Regulatory Affairs solutions and PPD FSP Pharmacovigilance solutions are designed to support this end-to-end life cycle approach. By integrating regulatory and PV expertise across products and markets, FSP models such as these reduce silos, improve accuracy and enhance efficiency in submissions.

Core capabilities include:

• Continuity from clinical development through post-market surveillance
• Global expertise with local regulatory and PV knowledge across regions
• Scalable, flexible resourcing models that adapt to changing workload demands
• Coordinated safety monitoring and regulatory affairs activities

Operationally, FSP models also provide access to advanced technologies and follow-the-sun global delivery models that improve speed, timelines and ROI. For example, advanced platforms such as the PPD SafetyNet Suite streamline PV workflows, enhance reporting capabilities and support proactive safety oversight. Rather than relying on reactive, fragmented execution models, sponsors can shift to integrated lifecycle management strategies that support both immediate operational needs and long-term growth.

Case for scalability: growing with your portfolio

Lifecycle maintenance becomes even more complex as organizations grow. New indications, geographic expansion, acquisitions, licensing changes and increasing case volumes all place additional demands on regulatory and PV teams. Maintaining consistency across products, regions and evolving regulatory requirements may quickly become difficult without scalable operational models in place. This is where FSP models provide long-term value.

By supporting standardized processes, integrated oversight and flexible resource scaling, FSP arrangements enable organizations to grow without compromising compliance or operational performance. They also create opportunities for knowledge transfer to internal teams and long-term partnership continuity, allowing internal teams to build stronger capabilities over time. Ultimately, lifecycle-enabled models allow organizations to navigate complexity and scale without compromising compliance or performance.

Sustaining success beyond approval

In today’s global regulatory environment, approval alone no longer defines success. Sustained compliance, operational readiness and lifecycle management are now critical components of long-term commercial viability. Organizations that integrate regulatory and PV planning early, invest in scalable systems and establish the right strategic partnerships are better equipped to adapt to evolving requirements and maintain products successfully across markets over time.

Maintaining a product in-market requires continuous compliance, monitoring, coordination and adaptation throughout the product life cycle. Organizations that embrace lifecycle thinking don’t just launch products; they sustain and scale them successfully.

Treat market entry as an ongoing operational strategy—not a checkpoint.

Explore how PPD FSP Regulatory Affairs solutions and PPD FSP Pharmacovigilance solutions enable you to build a scalable, lifecycle-driven approach to global expansion and long-term product success.